Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous FICB vs Systemic Opioids for Delirium in Hip Fracture
NCT02689024Phase 4Terminated
- Sponsor
- University of Amsterdam
- Start
- May 2016
- Primary completion
- Jul 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection, levobupivacaine and ropivacaine hydrochloride liposomal suspension injection in hip fracture, sponsored by University of Amsterdam. Primary endpoint: occurrence of delirium at 3 months. Started May 2016; status: terminated.
02
Drugs
bupivacaine hydrochloride 0.75% injectionlevobupivacaineropivacaine hydrochloride liposomal suspension injection
03
Conditions
hip fracture
Beyond the preview
Go deeper on NCT02689024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689024.